Neurodiagnostics Market Summary
The Global Neurodiagnostics Market size was valued at USD 9.78 Billion in 2025, and the market is projected to grow from USD 10.52 Billion in 2026 to USD 20.36 Billion by 2035, registering a CAGR of 7.6% during the forecast period 2026โ2035.ย Two catalysts anchor this trajectory: the U.S. National Institutes of Health committed over USD 12 billion to the BRAIN Initiative through 2026 [1], while the European Commission's Horizon Europe program earmarked EUR 1.8 billion for neuroscience and digital-health research through 2027 [2]. These large-scale public investments have compressed traditional adoption timelines and attracted private capital into cloud-enabled diagnostic platforms.
AI-augmented neuroimaging workstations capable of real-time volumetric analysis are replacing legacy film-based imaging suites and stand-alone electroencephalography consoles. Industry procurement databases reveal that hospital networks in North America and Western Europe allocated an anticipated USD 3.4 billion to improve installed neuroimaging fleets throughout 2023-2025 [3]. Blood-based biomarker panels for amyloid and tau proteins now complement classic imaging, providing clinicians with a faster, less intrusive means of detecting neurodegenerative diseases at early stages.
ย
North America accounts for over 38.5% of the Neurodiagnostics Market share, owing to strong hospital infrastructure and advantageous reimbursement routes. Asia-Pacific is expected to be the fastest-growing region with a CAGR of 10.0% through 2035, due to aggressive government digitalization initiatives in China, India and Japan. Europe accounts for around 27% of global sales, fueled by the EUโs Medical Device Regulation and growth in telehealth infrastructure. Regulatory modernization, demographic aging and AI maturation are all coming together to create a perfect storm for the Neurodiagnostics Market to continue to attract double-digit investment flows into the 2030s.
ย
Key Report Takeaways
โข By Product Type
- Reagents & consumables captured a 54.6% share of the Neurodiagnostics Market in 2025, reflecting recurring procurement cycles across hospital and reference laboratories.
- Gene therapy diagnostics are projected to advance at a 10.0% CAGR to 2035, spurred by companion diagnostic requirements linked to newly approved CNS gene therapies.
โข By Technology
- Neuroimaging technologies generated the largest revenue contribution in 2025, supported by fleet upgrades to AI-enabled MRI and PET-CT platforms.
- Neuroinformatics and AI analytics platforms are expanding at a 12.3% CAGR, the fastest of any technology sub-segment in the Neurodiagnostics Market.
โข By Geography
- North America maintained its dominance with 38.5% of 2025 revenues, anchored by Medicare coverage expansions for Alzheimer's diagnostics.
- Asia-Pacific is forecast to register a 10.0% CAGR through 2035, propelled by China's "Healthy China 2030" digital-health mandates and India's Ayushman Bharat hospital modernization program.
ย
Neurodiagnostics Market Size and Forecast (2021โ2035)
The Market Research Future (MRFR) triangulated methodology includes top-down revenue modeling based on corporate filings, bottom-up tracking of device shipments, and expert interviews with the heads of procurement at 120+ hospital systems internationally. Historical numbers (2021-2024) are based on audited sales, and the 2025 base year is based on a combination of the preliminary H1 actuals and consensus predictions. Forecast predictions (2026-2035) employ a compound growth model calibrated to macro-economic data, demographic aging curves and technology-adoption S-curves.

